Indication

For treatment in adults with primary hypercholesterolaemia (heterozygous familial and non‑familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL‑C goals with the maximum tolerated dose of a statin
    or
  • alone or in combination wtih other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Medicine details

Medicine name:
bempedoic acid (Nilemdo)
SMC ID:
SMC2363
Pharmaceutical company
Daiichi Sankyo UK Ltd
Submission type
Resubmission
Publication due date:
12 July 2021
SMC meeting date:
01 June 2021
Patient group submission deadline:
03 May 2021